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1. Introduction 
 
Opioids have been the basis of pain treatment for thousands of years, and they 
remain so today. Opium has been extracted from the poppy plant and used to treat pain 
for thousands of years but with little understanding of its mechanism of action. The pain 
relieving effect of opium and later of pure morphine has been successfully used against 
severe pain. Despite its severe side effects like respiratory depression, severe drowsiness, 
weakness, dizziness, slurred speech, nausea or vomiting, physical dependence and 
constipation etc., it’s still being used as a medicine for pain. 
Opioid peptides exert their effects through opioid receptors. Opioid receptors are 
members of the superfamily of G-protein-coupled receptors (GPCR). Three classical 
types of opioid receptors have been identified based on pharmacological and behavioral 
observations, namely µ-, δ-, and κ-receptors (MOR, DOR and KOR, respectively). 
Among those, µ-opioid receptors are targeted in the search for new drugs to suppress 
chronic pain. A major goal in opioid peptide research is the development of novel 
analgesics that could substitute morphine with less side-effects such as dependence, 
tolerance, respiratory depression and reward-seeking behavior. Endomorphin-1 (EM-1, 
H-Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (EM-2, H-Tyr-Pro-Phe-Phe-NH2) were 
initially isolated from bovine and later from human brain cortex. These peptides are the 
putative endogenous ligands of the µ-opioid receptor based on their high affinity and 
exceptional selectivity. Therefore they became important models in analgesic research. 
Its widely accepted that analgesic effects occur within the central nervous system (CNS) 
thus peptides should be able to cross the blood-brain barrier (BBB) intact. However, 
exogenous application of endomorphins is limited by short duration of action, low in vivo 
efficacy, poor metabolic stability and inability to cross the BBB. Even though the 
Endomorphins have been shown to have the longest half-lives among all endogenous 
opioid ligands, for their consideration as valuable therapeutic drugs it is essential to 
enhance their ability to enter the CNS and their resistance to enzymatic degradation. Such 
objectives may possibly be achieved through systematic modification of the peptide 
sequence.  
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2. Aims of the work 
The main goal of our research is to develop endomorphin analogues in order to 
accomplish increased proteolytic stabilities while retaining or enhancing biological 
properties. To achieve aforementioned objectives we incorporated several unnatural 
amino acids into the structure of Endomorphins. Designing the analogues with possible 
combination of these unnatural amino acids in the sequence, could provide useful 
information in terms of pharmacological properties. By considering these facts, our aims 
were: 
 
ü To synthesize the new endomorphin analogues with possible combination of 
Dmt1, Achc2, ∆Achc2/ ∆Acpc2, βPro2, Hyp2, βMePhe4 and pFPhe4 unnatural 
amino acids. 
ü To investigate the opioid receptor binding affinities and selectivities of newly 
synthesized analogues in radioligand receptor-binding studies. 
ü To test the functional properties of the highly potent analogues (selected based 
on receptor-binding assays results) in [35S]GTPγS binding assay.  
ü To evaluate the enzymatic resistance of highly potent analogues (selected based 
on receptor-binding and [35S]GTPγS binding assay results) against proteolytic 
degrading enzymes, such as dipeptidyl peptidase IV, carboxypeptidase Y, 
Amino peptidases etc.. 
ü To characterize blood-brain-barrier permeabilities using tritiated endomorphin-2 
analogues. 
ü To test the analgesic properties of highly potent endomorphin-2 analogues in in 
vivo chronic joint pain model. 
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3. Methods 
3.1. Peptide synthesis and purification 
A pool of endomorphin analogues were synthesized by manual solid phase 
peptide synthesis using N-α-t-Boc-protected amino acids and 4-methylbenzhydrylamine 
resin to obtain C-terminal amides. Obtained crude peptides were analyzed and purified 
using RP-HPLC on C18 column operating at 216 nm. Purity of peptides was determined 
by analytical RP-HPLC. The molecular weights of the peptides were confirmed by 
HRMS/ESI-MS. 
 
3.2. Radioligand binding assay 
The µ-receptor affinities were measured with [3H]DAMGO (1 nM, 25oC, 1 h, 
GF/C filter, glass tubes), and [3H]Ile5,6-deltorphin-2 (2 nM, 35oC, 45 min., GF/B filter, 
plastic tubes) was used for δ-receptor affinities.  
 
3.3. Ligand-stimulated [35S]GTPγS binding assay 
Ligand functional properties i.e. agonist or antagonist were measured based on 
efficacy (Emax) value. Non-specific binding was measured in the presence of 10 µM 
unlabeled GTPγS. 
 
3.4. Enzymatic degradation 
Evaluated ligand stabilities against proteolytic enzymes such as dipeptidyl 
peptidase IV, carboxypeptidase Y, amino peptidase etc.. 
 
All of the biological assays (methods 3.2 - 3.4) were performed using rat brain membrane 
preparation.  
 
3.5. Determination of n-octanol/water partition coefficient 
 Characterized the hydrophobicity of the ligands expressed as the ratio of peptide 
concentration found in the octanol phase to that found in the aqueous phase. 
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4. Results and Discussion 
In general, endomorphins are proteolytically less stable, although having the 
longest half-lives among the known mammalian opioid peptides. It is essential to enhance 
the CNS entry of endomorphins and their resistance to enzymatic degradation for 
considering them as valuable therapeutic drugs. In order to increase the proteolytic 
stability while retaining or enhancing the biological activity of endomorphins, we 
incorporated unnatural amino acids such as 2, 6-dimethyltyrosine1 (Dmt), (2S,4R)-
hydroxyproline2 (Hyp), (S)-β-proline2 (βPro), cis-2-aminocyclohexanecarboxylic acid2 
(cis-Achc), cis-2-aminocyclopentenecarboxylic acid2 (cis-∆Acpc), cis-2-
aminocyclohexenecarboxylic acid2 (cis-∆Achc), (2S,3S and 2R,3R)-β-
methylphyenylalanine4 (eβMePhe) and para-fluoro-phenylalanine4 (pFPhe) into the 
sequence of endomorphins. The chemical structures of incorporated unnatural amino 
acids were shown below. 
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The analysis of the binding data revealed that the co-application of (1S,2R)Achc2 
and (2S,3S)βMePhe4 in both endomorphins resulted comparably potent analogues in 
comparison with native peptides. These binding affinities were further enhanced by the 
combined substitution of Dmt1, (1S,2R)Achc2 and (2S,3S)βMePhe4. The results 
confirmed that single or combined use of Dmt1 increases the affinity for µ-opioid receptor 
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but, at the same time, decreases selectivity of ligands. Analogues containing the 
corresponding (2R,3R)βMePhe4 residue exhibited lower affinities than those including 
the other isomer (2S,3S)βMePhe4. Co-substitution with the halogenated pFPhe4 and 
Achc2 resulted in ligands with different potencies depending on the chirality of the 
alicyclic β-amino acids. Furthermore, it is also interesting to mention that pFPhe4 could 
compensate the detrimental effects of (1R,2S)Achc2 incorporation. Substitution of Hyp2 
resulted in decreased affinity to µ-opioid receptor, in contrast to affinity values measured 
with opioid selective antagonist naloxone in crude rat brain membrane. Insertion of (S)-
βPro2 resulted in lower affinity compared to that of parent endomorphin-2.  βPro2 
containing endomorphin-1 exhibited higher affinity to µ-opioid receptor in rat brain 
homogenate compared to the endomorphin-2. It can be assumed that only minor 
differences in structures (Trp/Phe) may be responsible for the observed changes in ligand 
binding. These results indicate that both the placement of a polar -OH group on the Pro2 
side chain and the extension of the backbone by a -CH2- group, while preserving the 
tertiary amide moiety of Pro has disadvantageous effects on MOR activity of EM-2. The 
observed propensity of binding potencies for unsaturated alicyclic β-amino acid 
containing analogues was similar to data obtained with saturated alicyclic β-amino acid 
analogues. Each ligand showed low to moderate binding affinities for δ-opioid receptors, 
indicates that these modifications provide µ-opioid receptor ligands. 
On the basis of the heterolog displacement binding data, the most potent 
analogues were selected for [35S]GTPγS functional assays to evaluate agonist/antagonist 
properties. To confirm opioid receptor functionality, the newly synthesized ligands were 
also assayed in the presence of the opioid antagonist naloxone. Potency (EC50) and 
efficacy (Emax) values were compared with those of the µ-receptor full agonist DAMGO 
(Emax=178%). Dose-dependent increases were observed for selected compounds in 
[35S]GTPγS binding. Both parent ligands exhibited comparable potencies, but lower 
efficacies (Emax=166% for endomorphin-1 and Emax=163% for endomorphin-2) was 
observed as compared to DAMGO, confirming that endomorphins are partial agonists, as 
reported earlier. Some of the tested compounds displayed the higher efficacies when 
compared to DAMGO, acting as full agonists. A few of compounds exhibited slightly 
less efficacies than that of DAMGO, which indicate partial agonist properties. No 
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significance difference was observed in efficacies measured with unsaturated alicyclic β-
amino acid containing analogues when compared to that of saturated alicyclic β-amino 
acid containing analogues. Analogue containing Dmt1, (1S,2R)Achc2, pFPhe4 displayed 
highest affinity and efficacy among all compounds. Incorporation of Hyp2 revealed 
moderate efficacy (Emax=148%), suggesting that it is a moderate partial agonist. The 
lowest efficacy (Emax=116%) was observed for analogue containing βPro2 among all 
analogues, proposing as a weak agonist. In the case of endomorphin-1, insertion of βPro2 
yielded the peptide with an increased efficacy, acting as an agonist. Interestingly, some 
compounds stimulated G-protein binding even in the presence of naloxone (10-5 M) 
therefore, we hypothesized that these ligands may bind to other G-protein coupled 
receptors or to non-opioid binding site.  
On the basis of the competition binding experiments, most potent analogues were 
selected for enzymatic degradation studies. Those analogues containing alicyclic β-amino 
acids demonstrated prolonged half-lives (>20 h) relative to the endomorphins (t1/2=5-7 
min), proving the enzymatic resistance of the new analogues. These results confirmed 
that Pro2 targeting modifications yields proteolytically stable endomorphins. 
The BBB plays a significant role in the treatment of CNS disorders. The rate of 
transendothelial transport of the peptides from the luminal (blood) side to the abluminal 
(brain) side was characterized. All of the tested analogues showed a significantly 
increased permeability in comparison with parent endomorphin-2. None of the peptides 
affected the viability of the cells significantly, not even in the highest concentrations, 
suggesting no cytotoxic effect was achieved. 
Based on the binding potencies, high potent endomorphin-2 analogues were 
selected to investigate the anti-allodynic effects at spinal level in a chronic joint pain 
model. All of the analogues elicited an antinociceptive effect in a concentration 
dependent manner.  
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5. Summary 
ü A small pool of endomorphin analogues were synthesized by systematic 
incorporation of unnatural amino acids, such as Dmt1, Achc2, ∆Acpc2/∆Achc2, 
Hyp2, βPro2, βMePhe4 and pFPhe4. Such modifications yielded analogues with 
increased proteolytic stabilities while retaining or enhancing the biological 
activity.  
ü Radioligand receptor-binding studies of newly synthesized analogues revealed 
that insertion of these amino acids resulted in moderate to highly potent 
compounds depending on the chiralities of the incorporated amino acids. The 
multiple modifications yielded the analogues with increased µ-receptor 
affinities, but with decreased selectivities.  
ü The ligand-stimulated [35S]GTPγS binding assay results revealed that some of 
the analogues showed higher efficacies relative to parent endomorphins. Most 
of the compounds retained agonist or partial agonist properties.  
ü Combined application of Dmt1, cis-(1S,2R)Achc2 and pFPhe4 resulted in the 
most potent analogue with a 1 order of magnitude higher receptor affinity 
compared to the parent endomorphin-2. Furthermore, it displayed the highest 
efficacy in the ligand-stimulated [35S]GTPγS binding assay, acting as a full 
agonist.  
ü Findings of this study revealed that unsaturation of alicyclic β-amino acids had 
no effect on binding affinities of endomorphin-2 in comparison with saturated 
alicyclic β-amino acids. 
ü The compound bearing cis-(1S,2R)∆Acpc2 displayed an equal µ-opioid receptor 
affinity with high selectivity compared to the parent compound endomorphin-2. 
ü Dmt1, (1S,2R)Acpc2, and (1S,2R)Achc2 containing endomorphin-2 analogues 
have displayed higher blood-brain-barrier permeabilities in comparison with the 
parent ligand with no viability of endothelial cells. None of the tested ligands 
had a cytotoxic effect on viability of rat brain endothelial cells. 
ü Among all the tested ligands Dmt-(1S,2R)Achc-Phe-(2S,3S)βMePhe-NH2 
elicited antinociception comparable with morphine in a chronic pain model. 
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Design, Synthesis, Pharmacological Evaluation, and Structure-Activity Study of 
Novel Endomorphin Analogues with Multiple Structural Modifications.  
Journal of Medicinal Chemistry, 54: 1462-1472.  
Impact Factor: 5.207 
 
2012: 
2. Mallareddy, J. R.; Tóth, G.; Fazakas, C.; Molnár, J.; Nagyőszi, P.; Lipkowski, A. W.; 
Krizbai, I.A.; Wilhelm, I. Transport Characteristics of Endomorphin-2 Analogues in 
Brain Capillary Endothelial Cells.  
Chemical Biology & Drug Design, 79: 507-513. 
Impact Factor: 2.527 
 
3. Tóth, G.; Mallareddy, J. R.; Tóth, F.; Lipkowski, A. W.; Tourwé, D. Radiotracers, 
Tritium Labelling of Neuropeptides.  
Arkivoc, (v): 163-174. 
Impact Factor: 1.096 
 
Sum of impact factor: 8.83 
 
List of not related to the thesis publications 
2012: 
1. Németh, K.; Mallareddy, J. R.; Domonkos, C.; Visy, J.; Géza, T.; Péter, A. 
Stereoselective Analysis of Tetrapeptide Diastereomers: Resolution of Biologically 
Active Endomorphin Analogues by Capillary Electrophoresis using Cyclodextrins. 
Journal of Pharmaceutical and Biomedical Analysis (under review) 
 
 
 
 
9
2. Kovács, G.; Petrovszki, Z.; Mallareddy, J. R.; Tóth, G.; Benedek, G.; Horváth, G. 
Characterization of Antinociceptive Potency of Endomorphin-2 Derivatives with 
Unnatural Amino Acids.  
Acta Physiologica Hungarica (in print) 
Impact Factor: 1.226 
 
2011: 
3. Vandormael, B.; Wachter, R. D.; Martins, J. C.; Hendrickx, P. M. S.; Keresztes, A.; 
Ballet, S.; Mallareddy, J. R.; Tóth, F.; Tóth, G.; Tourwé, D. Asymmetric Synthesis 
and Conformational Analysis by NMR and MD of Aba- and α-MeAba-Containing 
Dermorphin Analogs.  
ChemMedChem, 6: 2035-2047. 
Impact Factor: 3.306 
 
Sum of impact factor: 4.532 
 
Manuscripts under preparation 
1. Borics, A.; Mallareddy, J. R.; Tímári, I.; Ko ̈vér, K. E.; Keresztes, A.; Tóth, G. The 
Effect of Pro2 Modifications on the Structural and Pharmacological Properties of 
Endomorohin-2.  
 
2. Tóth, F.; Kleczkowska, P.; Lipkowski, A. W.; Mallareddy, J. R.; Tourwé, D.; Tóth, 
G.; Bojnik, E.; Benyhe, S. Synthesis and Binding Characteristics of a Neurotensin-
like Peptide: [3H]Neuromedin-N. 
 
Oral presentations 
1. Mallareddy, J. R.; Borics, A.; Keresztes, A.; Tóth, G. “Design and Synthesis of 
Pharmacologically Active Endomorphins” in Annual Meeting of the Peptide 
Committee of the Hungarian Academy of Sciences, Balatonszemes, Hungary. (2011) 
 
 
10
2. Mallareddy, J. R. “Effects of Unnatural Amino Acids on Bioactivity of 
Endomorphins” in Young Organic Chemist symposium organized by University of 
Szeged, Szeged, Hungary. (2011) 
3. Mallareddy, J. R. “Design, Synthesis and Biological Evaluation of Chemically 
Multiple Modified Endomorphins” in Young Organic Chemist symposium 
organized by Department of Chemistry, University of Szeged, Szeged, Hungary. 
(2010) 
4. Mallareddy, J. R.; Keresztes, A.; Tóth, G “Investigations of Endomorphin-2 
Biosynthesis” in Annual Meeting of the Peptide Committee of the Hungarian 
Academy of Sciences, Balatonszemes, Hungary. (2010) 
 
Posters 
 
1. Mallareddy, J. R.; Borics, A.; Keresztes, A.; Tóth, G. Influence of Proline Mimetics 
on Bioactivity of Endomorphin-2. 4th European Conference on Chemistry for Life 
Sciences, Budapest, Hungary. (2011) P170 
2. Tóth, F.; Kleczkowska, P.; Lipkowski, A. W.; Mallareddy, J. R.; Tóth, G.; Tomboly, 
Cs.; Bojnik, E.; Borsodi, A.; Benyhe, S. Synthesis and Binding Characteristics of a 
Neurotensin-like Peptide: [3H]Neuromedin N. International Society for 
Neurochemistry, Athens, Greece. (2011) 
3. Tóth, G.; Mallareddy, J. R.; Tóth, F.; Lipkowski, A. W.; Tourwé, D. Radiotracers-
Tritium Labelled Neuropeptides. 4th European Conference on Chemistry for Life 
Sciences, Budapest, Hungary. (2011) P175 
4. Mallareddy, J. R.; Borics, A.; Keresztes, A.; Tóth, G. Design, Synthesis and 
Pharmacological Evaluation of Novel Endomorphin analogues with Multiple 
Structural Modifications. 8th European Opioid Conference, Krakow, Poland. (2011) 
PS I – 7 
5. Tóth, G.; Mallareddy, J. R.; Borics, A.; Ko ̈vér, K. E.; Keresztes, A. Design, 
Synthesis and Biological Evaluation of Novel Endomorphins with Multiple Structural 
Modifications. Proceedings of 31st European Peptide Symposium, European Peptide 
Society, Copenhagen, Denmark. Page 454-455. (2010) 
 
 
 
11
6. Tomczyszyn, A.; Lipkowski, A. W.; Toth, G.; Keresztes, A.; Mallareddy, J. R.; 
Misicka, A. Synthesis of Tritiated Ligand for Binding Assays to Tachykinin 
Receptors. 20th Polish Peptide Symposium, Wladyslawowo, Poland. (2010) 
 
Declaration of co-author renunciation  
Undersigned, I declare that the candidate’s thesis and the jointly published papers in 
which the candidate’s role is of key of important weren’t used and will never be used in 
the future for obtaining scientific degree.  
 
Mallareddy, J. R.; Tóth, G.; Fazakas, C.; Molnár, J.; Nagyőszi, P.; Lipkowski, A. W.; 
Krizbai, I.A.; Wilhelm, I. Transport Characteristics of Endomorphin-2 Analogues in 
Brain Capillary Endothelial Cells. Chem. Biol. Drug Des. 2012, 79, 507-513. 
 
Tóth, G.; Mallareddy, J. R.; Tóth, F.; Lipkowski, A. W.; Tourwé, D. Radiotracers, 
Tritium Labelling of Neuropeptides. Arkivoc, 2012, (v), 163-174. 
 
Fazakas Csilla   ………………………………… 
Judit Molnár   ………………………………… 
Péter Nagyőszi  ………………………………… 
Dr. Fanni Tóth   ………………………………… 
Dr. István A. Krizbai  ………………………………… 
Dr. Imola Wilhelm  ………………………………… 
Dr. Géza Tóth   ………………………………… 
 
 
